Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company specializing in the development of personalized immune therapies for cancer. Headquartered in Bethesda, Maryland, the company utilizes its proprietary DCVax platform, which employs activated dendritic cells to stimulate the patient's immune response against cancer. Currently, Northwest Biotherapeutics is advancing its product candidates DCVax-L, in Phase III clinical trials for glioblastoma multiforme, and DCVax-Direct, in Phase I/II trials for various inoperable solid tumors. The company's therapies aim to enhance immune responses, potentially offering significant improvements in survival and quality of life compared to existing treatments, which often have limited efficacy and undesirable side effects. Established in 1996, Northwest Biotherapeutics continues to focus on developing innovative cancer therapies that address unmet medical needs.